Akeso is developing next-generation therapies for high-burden diseases driven by fibrosis, inflammation, and metabolic dysfunction — across hepatology, immunology, neurology, and women’s health.

The company’s lead asset, AD64, is a potentially best-in-class therapeutic targeting a novel anti-fibrotic pathway to halt and reverse the progression of metabolic dysfunction-associated steatohepatitis (MASH) – a silent epidemic.

Building on the mechanistic foundation of AD64, Akeso is advancing a diversified pipeline of novel candidates designed to treat:

• Lung, renal, and pancreatic sclerosis, where fibrotic remodeling underlies progressive organ failure
• Inflammatory bowel disease (IBD) and gout, by targeting chronic inflammation and metabolic dysregulation at the source
• Attention Deficient Hyperactivity Disorder (ADHD), with a focus on inflammation-linked subtypes where current therapies show limited efficacy
• Pre-term birth, via a proprietary Omega-3-based intervention aimed at reducing complications and supporting full gestation

Akeso’s proprietary discovery platform systematically identifies therapeutic targets where conventional approaches have failed – enabling the development of disease-modifying therapies with scalable production, strong scientific rationale, and durable intellectual property potential.

Our Differentiation

• Lead asset targeting blockbuster MASH market
• Broad, multi-indication pipeline with platform leverage
• Focused on large, underserved patient populations
• Multiple near-term inflection points (preclinical → clinical)